newsfilter
← Latest News
GlobeNewswire·

ProKidney Reports Full Year 2024 Financial Results and Business Highlights

Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel's path to market in the U.S., the release of positive Phase 2 data, restarting manufacturing, and securing $140